Showing results (701-710 of 1,068) with videos related to
Sort By:
Pageof 107
Journal of Pharmacokinetics and Pharmacodynamics|November 2, 2013
On the maintenance of hepatocyte intracellular pH 7.0 in the in-vitro metabolic stability assayLeonid M Berezhkovskiy, Susan Wong, Jason S HalladayJournal of Pharmacokinetics and Pharmacodynamics|August 6, 2013
A physiologically-based pharmacokinetic (PBPK) model of squalene-containing adjuvant in human vaccinesMillion A Tegenge, Robert J MitkusJournal of Pharmacokinetics and Pharmacodynamics|August 15, 2013
Simultaneous optimal experimental design for in vitro binding parameter estimationC Steven Ernest, Mats O Karlsson, Andrew C HookerJournal of Pharmacokinetics and Pharmacodynamics|November 21, 2015
Stochastic nonlinear mixed effects: a metformin case studyBrett Matzuka, Jason Chittenden, Jonathan Monteleone, et al.Journal of Pharmacokinetics and Pharmacodynamics|February 4, 2016
Methods and strategies for assessing uncontrolled drug-drug interactions in population pharmacokinetic analyses: results from the International Society of Pharmacometrics (ISOP) Working GroupPeter L Bonate, Malidi Ahamadi, Nageshwar Budha, et al.Journal of Pharmacokinetics and Pharmacodynamics|September 4, 2015
Prediction and validation of enzyme and transporter off-targets for metforminSook Wah Yee, Lawrence Lin, Matthew Merski, et al.Journal of Pharmacokinetics and Pharmacodynamics|August 12, 2015
Modelling of drug-induced QT-interval prolongation: estimation approaches and translational opportunitiesEleonora Marostica, Karel Van Ammel, Ard Teisman, et al.Journal of Pharmacokinetics and Pharmacodynamics|September 6, 2015
Semi-mechanistic kidney model incorporating physiologically-relevant fluid reabsorption and transporter-mediated renal reabsorption: pharmacokinetics of γ-hydroxybutyric acid and L-lactate in ratsRutwij A Dave, Marilyn E MorrisJournal of Pharmacokinetics and Pharmacodynamics|August 21, 2015
Modeling population heterogeneity in viral dynamics for chronic hepatitis C infection: Insights from Phase 3 telaprevir clinical studiesEric L Haseltine, Holly Kimko, Haobin Luo, et al.Journal of Pharmacokinetics and Pharmacodynamics|January 7, 2015
Simulations of site-specific target-mediated pharmacokinetic models for guiding the development of bispecific antibodiesVaishali L Chudasama, Anup Zutshi, Pratap Singh, et al.Pageof 107